PAPER Grober E, Wang C, Kitner-Triolo M, Lipton RB, Kawas C, Resnick SM

Prognostic Value of Learning and Retention Measures from the Free and Cued Selective Reminding Test to Identify Incident Mild Cognitive Impairment.

J Int Neuropsychol Soc. 2021 Mar 22;:1-8. PubMed: 33745492

PAPER Chauhan PS, Mishra M, Koul B, Sharma M, Yadav D

Modifiable Risk Factors Associated with Alzheimer's Disease with Special Reference to Sleep Disturbance.

CNS Neurol Disord Drug Targets. 2021 Mar 19; PubMed: 33745437

PAPER Li Q, Zhang Y, Liang H, Gong H, Jiang L, Liu Q, Shen L

Deep learning based neuronal soma detection and counting for Alzheimer's disease analysis.

Comput Methods Programs Biomed. 2021 May;203:106023. Epub 2021 Mar 10 PubMed: 33744751

PAPER Lemprière S

Antibody targets apolipoprotein E to remove amyloid-β deposits.

Nat Rev Neurol. 2021 Apr;17(4):194. PubMed: 33750931

PAPER Michiels L, Van Weehaeghe D, Vandenberghe R, Demeestere J, Van Laere K, Lemmens R

The Role of Amyloid PET in Diagnosing Possible Transmissible Cerebral Amyloid Angiopathy in Young Adults with a History of Neurosurgery: A Case Series.

Cerebrovasc Dis. 2021;50(3):356-360. Epub 2021 Mar 19 PubMed: 33744891

PAPER Gustafson DR

Epidemiology Informs Randomized Clinical Trials of Cognitive Impairments and Late-Onset, Sporadic Dementias.

J Neurol Neuromedicine. 2018;3(5):13-18. PubMed: 33748680

PAPER Aum S, Choe S, Cai M, Jerng UM, Lee JH

Moxibustion for cognitive impairment: a systematic review and meta-analysis of animal studies.

Integr Med Res. 2021 Jun;10(2):100680. Epub 2020 Oct 14 PubMed: 33747784

PAPER Karki HP, Jang Y, Jung J, Oh J

Advances in the development paradigm of biosample-based biosensors for early ultrasensitive detection of alzheimer's disease.

J Nanobiotechnology. 2021 Mar 9;19(1):72. PubMed: 33750392

PAPER Bai D, Fan J, Li M, Dong C, Gao Y, Fu M, Huang G, Liu H

Effects of Folic Acid Combined with DHA Supplementation on Cognitive Function and Amyloid-β-Related Biomarkers in Older Adults with Mild Cognitive Impairment by a Randomized, Double Blind, Placebo-Controlled Trial.

J Alzheimers Dis. 2021;81(1):155-167. PubMed: 33749643

Yaisa Andrews-Zwilling

Havertown, United States

Christian Hoelscher on Donanemab Confirms: Clearing Plaques Slows Decline—By a Bit

COMMENT How can anyone claim that this study confirms the amyloid hypothesis? While donanemab is able to clear the brains of patients of amyloid very effectively, the impact on cognition is only marginal, and perhaps of little relevance in the daily life of AD pa

Zachary Green

United States

Cohorts Band Together to Get Global FTD Trials Going

RESEARCH NEWS 2021-03-23 Research News Compared to Alzheimer’s disease, frontotemporal lobar degeneration is far rarer and more diverse in terms of its clinical manifestations and their underlying genetic and neuropathological causes. This makes the illness maddeningly difficult

Li Gan

Weill Cornell Medicine
United States

Scott Ayton on Donanemab Confirms: Clearing Plaques Slows Decline—By a Bit

COMMENT I was sadly disappointed by the study data. It is curious that there has been little discussion about the acceleration to brain-volume loss (whole brain and ventricular enlargement) in patients treated with donanemab. To preempt the tortured rationalizati